1. Scrip
  2. >>Business

Sanofi Extends Cancer Ambitions With IL-2 Drug And Keytruda Combination

Seeking Cancer Blockbuster To Match Dupixent Success

 
• By Andrew McConaghie

Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.

Sanofi_Berlin
Dupixent is helping to power the new Sanofi, but the company wants to become a major player in oncology as well.

Sanofi is to work with Merck & Co. to study its interleukin-2 candidate in combination with immunotherapy blockbuster Keytruda in patients with various cancers.

The drug, named THOR-707, is the lead asset from Synthorx, the San Diego-based immuno-oncology company it acquired last December for $2.5bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.